Academic Journal
Medication effects on cue-induced craving in the human laboratory are associated with return to heavy drinking in randomized clinical trials for alcohol use disorder: A follow-up meta-analysis.
| Τίτλος: | Medication effects on cue-induced craving in the human laboratory are associated with return to heavy drinking in randomized clinical trials for alcohol use disorder: A follow-up meta-analysis. |
|---|---|
| Συγγραφείς: | Nieto SJ; Department of Psychology, University of California at Los Angeles, Los Angeles, CA, USA.; Department of Psychiatry and Behavioral Neurosciences, Wayne State University School of Medicine, Detroit, MI, USA., Du H; Department of Psychology, University of California at Los Angeles, Los Angeles, CA, USA., Meredith LR; Department of Psychology, University of California at Los Angeles, Los Angeles, CA, USA., Donato S; Department of Psychology, University of California at Los Angeles, Los Angeles, CA, USA., Baskerville WA; Department of Psychology, University of California at Los Angeles, Los Angeles, CA, USA., McManus KR; Department of Psychology, University of California at Los Angeles, Los Angeles, CA, USA., Magill M; Center for Alcohol and Addiction Studies, Brown University School of Public Health, Providence, RI, USA., Ray LA; Department of Psychology, University of California at Los Angeles, Los Angeles, CA, USA.; Department of Psychiatry and Biobehavioral Sciences, University of California at Los Angeles, Los Angeles, CA, USA. |
| Πηγή: | Addiction (Abingdon, England) [Addiction] 2026 Jul; Vol. 121 (7), pp. 1671-1680. Date of Electronic Publication: 2026 Mar 08. |
| Τύπος έκδοσης: | Journal Article; Meta-Analysis; Review |
| Γλώσσα: | English |
| Στοιχεία περιοδικού: | Publisher: Wiley-Blackwell Country of Publication: England NLM ID: 9304118 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1360-0443 (Electronic) Linking ISSN: 09652140 NLM ISO Abbreviation: Addiction Subsets: MEDLINE |
| Imprint Name(s): | Publication: Oxford : Wiley-Blackwell Original Publication: Abingdon, Oxfordshire, UK : Carfax Pub. Co., c1993- |
| Ιατρικοί όροι (MeSH): | Alcohol Deterrents*/therapeutic use , Alcoholism*/drug therapy , Alcoholism*/psychology , Craving*/drug effects , Cues*, Alcohol Drinking/psychology ; Alcohol Drinking/drug therapy ; Naltrexone/therapeutic use ; Taurine/analogs & derivatives ; Taurine/therapeutic use ; Humans ; Acamprosate ; Follow-Up Studies ; Randomized Controlled Trials as Topic |
| Περίληψη: | Background and Aims: The alcohol cue-reactivity paradigm is widely used to test the initial efficacy of potential medications for alcohol use disorder (AUD); however, there is limited quantitative evidence demonstrating that medication effects on cue-induced craving are associated with efficacy in clinical trials. This meta-analysis examined whether medication effects on cue-induced alcohol craving are associated with medication effects in randomized clinical trials (RCTs). Methods: Follow-up meta-analysis of RCTs. Participants included people who engaged in heavy drinking or have AUD. Medications were compared with a placebo control. We computed medication effect sizes (Cohen's d) for cue-induced craving (k Results: Medication effect sizes on cue-induced craving were positively associated with medication effect sizes on percent participants who returned to heavy drinking [ INLINEMATH = 1.06, standard error (SE) = 0.63, one-sided P = 0.04, two-sided P = 0.09; k Conclusions: Medications that produce greater reductions in cue-induced alcohol craving appear to be associated with lower rates of return to heavy drinking, but not consistently with other drinking outcomes. This pattern indicates that the cue-reactivity paradigm has limited and outcome-specific translational validity rather than functioning as a universal indicator of clinical efficacy. (© 2026 Society for the Study of Addiction.) |
| References: | Bujarski S, Ray LA. Experimental psychopathology paradigms for alcohol use disorders: applications for translational research. Behav Res Ther. 2016;86:11–22. https://doi.org/10.1016/j.brat.2016.05.008. Monti PM, Binkoff JA, Abrams DB, Zwick WR, Nirenberg TD, Liepman MR. Reactivity of alcoholics and nonalcoholics to drinking cues. J Abnorm Psychol. 1987;96(2):122–126. https://doi.org/10.1037/0021-843X.96.2.122. Meredith LR, Burnette EM, Nieto SJ, Du H, Donato S, Grodin EN, et al. Testing pharmacotherapies for alcohol use disorder with cue exposure paradigms: a systematic review and quantitative synthesis of human laboratory trial methodology. Alcohol Clin Exp Res. 2023;47(9):1629–1645. https://doi.org/10.1111/acer.15143. Carter BL, Tiffany ST. Meta‐analysis of cue‐reactivity in addiction research. Addiction. 1999;94(3):327–340. https://doi.org/10.1046/j.1360-0443.1999.9433273.x. Monti PM, Rohsenow DJ, Hutchison KE, Swift RM, Mueller TI, Colby SM, et al. Naltrexone's effect on cue‐elicited craving among alcoholics in treatment. Alcohol Clin Exp Res. 1999;23(8):1386–1394. https://doi.org/10.1111/j.1530-0277.1999.tb04361.x. Miranda R, Ray L, Blanchard A, Reynolds EK, Monti PM, Chun T, et al. Effects of naltrexone on adolescent alcohol cue reactivity and sensitivity: an initial randomized trial. Addict Biol. 2014;19(5):941–954. https://doi.org/10.1111/adb.12050. O'Malley SS, Krishnan‐Sarin S, Farren C, Sinha R, Kreek MJ. Naltrexone decreases craving and alcohol self‐administration in alcohol‐dependent subjects and activates the hypothalamo‐pituitary‐adrenocortical axis. Psychopharmacology. 2002;160(1):19–29. https://doi.org/10.1007/s002130100919. Hammarberg A, Jayaram‐Lindström N, Beck O, Franck J, Reid MS. The effects of acamprosate on alcohol‐cue reactivity and alcohol priming in dependent patients: a randomized controlled trial. Psychopharmacology. 2009;205(1):53–62. https://doi.org/10.1007/s00213-009-1515-6. Ray LA, Du H, Green R, Roche DJO, Bujarski S. Do behavioral pharmacology findings predict clinical trial outcomes? A proof‐of‐concept in medication development for alcohol use disorder. Neuropsychopharmacology. 2021;46(3):519–527. https://doi.org/10.1038/s41386-020-00913-3. Nieto SJ, Du H, Meredith LR, Donato S, Magill M, Ray LA. Leveraging meta‐regression to test if medication effects on cue‐induced craving are associated with clinical efficacy. Psychopharmacology. 2024;241(8):1679–1689. https://doi.org/10.1007/s00213-024-06589-7. Magill M, Ray L, Kiluk B, Hoadley A, Bernstein M, Tonigan JS, et al. A meta‐analysis of cognitive‐behavioral therapy for alcohol or other drug use disorders: treatment efficacy by contrast condition. J Consult Clin Psychol. 2019;87(12):1093–1105. https://doi.org/10.1037/ccp0000447. Ray LA, Meredith LR, Kiluk BD, Walthers J, Carroll KM, Magill M. Combined pharmacotherapy and cognitive behavioral therapy for adults with alcohol or substance use disorders: A systematic review and meta‐analysis. JAMA Netw Open. 2020;3(6):e208279. https://doi.org/10.1001/jamanetworkopen.2020.8279. Falk DE, O'Malley SS, Witkiewitz K, Anton RF, Litten RZ, Slater M, et al. Evaluation of drinking risk levels as outcomes in alcohol pharmacotherapy trials: a secondary analysis of 3 randomized clinical trials. JAMA Psychiatry. 2019;76(4):374–381. https://doi.org/10.1001/jamapsychiatry.2018.3079. Belnap MA, McManus KR, Grodin EN, Ray LA. Endpoints for pharmacotherapy trials for alcohol use disorder. Pharm Med. 2024;38(4):291–302. https://doi.org/10.1007/s40290-024-00526-x. Donato S, Meredith LR, Nieto SJ, Bujarski S, Ray LA. Medication development for Aud: a systematic review of clinical trial methodology. Alcohol. 2024;120:194–203. https://doi.org/10.1016/j.alcohol.2024.06.007. Nieto SJ, Grodin EN, Aguirre CG, Izquierdo A, Ray LA. Translational opportunities in animal and human models to study alcohol use disorder. Transl Psychiatry. 2021;11(1):496. https://doi.org/10.1038/s41398-021-01615-0. Witkiewitz K, Falk DE, Litten RZ, Hasin DS, Kranzler HR, Mann KF, et al. Maintenance of World Health Organization risk drinking level reductions and posttreatment functioning following a large alcohol use disorder clinical trial. Alcohol Clin Exp Res. 2019;43(5):979–987. https://doi.org/10.1111/acer.14018. |
| Grant Information: | F31AA029295 United States AA NIAAA NIH HHS; F32AA029288 United States AA NIAAA NIH HHS; K24AA025704 United States AA NIAAA NIH HHS; R01AA029701-01S1 United States AA NIAAA NIH HHS; R21AA029771 United States AA NIAAA NIH HHS |
| Contributed Indexing: | Keywords: alcohol cue‐reactivity; alcohol use disorder; behavioral pharmacology; human laboratory; medications; randomized clinical trials |
| Substance Nomenclature: | N4K14YGM3J (Acamprosate) 0 (Alcohol Deterrents) 5S6W795CQM (Naltrexone) 1EQV5MLY3D (Taurine) |
| Entry Date(s): | Date Created: 20260309 Date Completed: 20260624 Latest Revision: 20260626 |
| Update Code: | 20260626 |
| DOI: | 10.1111/add.70373 |
| PMID: | 41797424 |
| Βάση Δεδομένων: | MEDLINE |
καταχωρήστε σχόλιο πρώτοι!